secwatch / observer
8-K filed May 7, 2026, 7:59 PM ET ticker DARE CIK 0001401914
other material confidence high sentiment neutral materiality 0.50

Daré Bioscience closes $975k Regulation A offering of Series A Preferred and warrants

Dare Bioscience, Inc.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Dare Bioscience, Inc. issued 195,010 Investor Units, each consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants to purchase up to 390,020 shares of commo of unit to public investors in Regulation A offering for at an offering price of $5.00 per unit.

Security
unit
Shares
195,010 Investor Units, each consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants to purchase up to 390,020 shares of commo
Purchaser
public investors in Regulation A offering
Consideration
at an offering price of $5.00 per unit
Exact text from the filing
completed closings of its previously announced Regulation A offering of up to 4,854,000 units (each, an “Investor Unit” and collectively the “Investor Units”), each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and two warrants, each to purchase one share of our common stock (“Investor Warrants”), with each Investor Unit being offered at an offering price of $5.00 (the “Offering”). The closings occurred on each of May 1, 4, 5 and 6, 2026. In connection therewith, we issued an aggregate of 195,010 Investor Units consisting of 195,010 shares of Series A Preferred Stock and Investor Warrants to purchase up to 390,020 shares of our common stock.
View on SEC.gov

Browse all equity issuances →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR
accession 0001401914-26-000021
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.